Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Esperion Therapeutics, Inc. Logo
Develops and commercializes oral medicines to reduce cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops drugs targeting the androgen receptor's N-terminal domain for prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Pharmaceutical company developing and commercializing treatments for rare diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
A biopharmaceutical company developing vaccines and offering CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Clinical-stage biotech developing locally delivered, extended-release therapies.
United States of America
EPRX
eureKING Logo
A SPAC created to acquire European biomanufacturing companies.
France
KINGS
EuroAPI Logo
Develops and manufactures APIs and provides CDMO services for complex molecules.
France
EAPI
Eurobio Scientific Logo
Specializes in in vitro diagnostics for transplantation, oncology, and infectious diseases.
France
ALERS
European Institute of Science AB Logo
Develops and sells diagnostic solutions and instruments for veterinary health.
Sweden
EURI B

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.